• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

社会人口统计学和遗传风险因素对 5 种常见药物类别的药物依从性和持久性的影响。

Socio-demographic and genetic risk factors for drug adherence and persistence across 5 common medication classes.

机构信息

Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.

CHDS - Health Data Science Center, Human Technopole, Milan, Italy.

出版信息

Nat Commun. 2024 Oct 23;15(1):9156. doi: 10.1038/s41467-024-53556-z.

DOI:10.1038/s41467-024-53556-z
PMID:39443518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11500092/
Abstract

Low drug adherence is a major obstacle to the benefits of pharmacotherapies and it is therefore important to identify factors associated with discontinuing or being poorly adherent to a prescribed treatment regimen. Using high-quality nationwide health registry data and genome-wide genotyping, we evaluate the impact of socio-demographic and genetic risk factors on adherence and persistence for 5 common medication classes that require long-term, regular therapy (N = 1,814,591 individuals from Finnish nationwide registries, 217,005 with genetic data from Finland and Estonia). Need for social assistance and immigration status show a notable negative effect on persistence and adherence across the examined medications (odd ratios between 0.48 and 0.82 for persistence and between 1.1% to 4.3% decrease in adherence) while demographic and health factors show comparably modest or inconsistent effects. A genome-wide scan does not identify genetic variants associated with the two phenotypes, while some pharmacogenes (i.e. CYP2C9 and SLCO1B1) are modestly associated with persistence, but not with adherence. We observe significant genetic correlations between medication adherence and participation in research studies. Overall, our findings suggest that socio-economically disadvantaged groups would benefit from targeted interventions to improve the dispensing and uptake of pharmacological treatments.

摘要

药物依从性低是药物治疗效益的主要障碍,因此,确定与停止或不遵守规定治疗方案相关的因素非常重要。本研究使用高质量的全国健康登记数据和全基因组基因分型,评估了社会人口学和遗传风险因素对 5 种常见需要长期、规律治疗的药物类别的依从性和持久性的影响(来自芬兰全国登记处的 1814591 名个体,其中 217005 名个体具有来自芬兰和爱沙尼亚的遗传数据)。社会援助需求和移民身份对所检查药物的持久性和依从性有显著的负面影响(持久性的比值比在 0.48 到 0.82 之间,依从性下降 1.1%至 4.3%),而人口统计学和健康因素的影响则相对较小或不一致。全基因组扫描未识别出与这两种表型相关的遗传变异,而一些药物基因(即 CYP2C9 和 SLCO1B1)与持久性中度相关,但与依从性无关。我们观察到药物依从性和参与研究之间存在显著的遗传相关性。总的来说,我们的研究结果表明,社会经济处于不利地位的群体将受益于有针对性的干预措施,以改善药物治疗的配药和使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654e/11500092/001fee13717a/41467_2024_53556_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654e/11500092/89cbe3a5e79a/41467_2024_53556_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654e/11500092/a3ab1964f47f/41467_2024_53556_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654e/11500092/70f1b98c1ff0/41467_2024_53556_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654e/11500092/f6a87ff40437/41467_2024_53556_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654e/11500092/001fee13717a/41467_2024_53556_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654e/11500092/89cbe3a5e79a/41467_2024_53556_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654e/11500092/a3ab1964f47f/41467_2024_53556_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654e/11500092/70f1b98c1ff0/41467_2024_53556_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654e/11500092/f6a87ff40437/41467_2024_53556_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654e/11500092/001fee13717a/41467_2024_53556_Fig5_HTML.jpg

相似文献

1
Socio-demographic and genetic risk factors for drug adherence and persistence across 5 common medication classes.社会人口统计学和遗传风险因素对 5 种常见药物类别的药物依从性和持久性的影响。
Nat Commun. 2024 Oct 23;15(1):9156. doi: 10.1038/s41467-024-53556-z.
2
The frequency of major , and variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing.亚洲、夏威夷原住民和太平洋岛民女性亚组中主要和变体的频率:对个体化他汀类药物剂量的影响。
Pharmacogenomics. 2023 May;24(7):381-398. doi: 10.2217/pgs-2023-0043. Epub 2023 May 24.
3
Identification of Genetic Variants Associated with Pravastatin and Pitavastatin Pharmacokinetics.与普伐他汀和匹伐他汀药代动力学相关的基因变异的鉴定。
Clin Pharmacol Ther. 2025 Jun;117(6):1763-1774. doi: 10.1002/cpt.3623. Epub 2025 Mar 3.
4
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.临床药物遗传学实施联盟指南:SLCO1B1、ABCG2 和 CYP2C9 基因型与他汀类药物相关的肌肉骨骼症状。
Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11.
5
Interventions to increase adherence to medications for tobacco dependence.提高烟草依赖药物依从性的干预措施。
Cochrane Database Syst Rev. 2019 Aug 16;8(8):CD009164. doi: 10.1002/14651858.CD009164.pub3.
6
Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.美国退伍军人事务部药剂使用者中可操作的药物遗传学变异体和 A 级药物的预计流行率。
JAMA Netw Open. 2019 Jun 5;2(6):e195345. doi: 10.1001/jamanetworkopen.2019.5345.
7
Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care.影响英国初级保健中患者坚持和遵守处方膀胱过度活动症药物因素的定性分析。
Adv Ther. 2019 Nov;36(11):3110-3122. doi: 10.1007/s12325-019-01098-y. Epub 2019 Sep 26.
8
Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.在接受医疗保险处方药计划(Medicare Part D)的透析患者中,药物治疗的依从性和持续性:福利类型和福利阶段的比较。
J Manag Care Spec Pharm. 2014 Aug;20(8):862-76. doi: 10.18553/jmcp.2014.20.8.862.
9
Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.SLCO1B1(c.521T>C,rs4149056)和 ABCG2(c.421C>A,rs2231142)基因的功能丧失多态性与瑞舒伐他汀的不良事件相关:一项病例对照研究。
Eur J Clin Pharmacol. 2022 Feb;78(2):227-236. doi: 10.1007/s00228-021-03233-7. Epub 2021 Oct 19.
10
The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis.SLCO1B1、载脂蛋白 E 和 CYP2C9 基因与氟伐他汀的血脂反应相关性:一项荟萃分析。
Pharmacogenet Genomics. 2018 Dec;28(12):261-267. doi: 10.1097/FPC.0000000000000356.

引用本文的文献

1
Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data.了解低他汀类药物依从性的原因及后果:来自英国生物银行初级保健数据的证据。
BMC Med. 2025 Jul 22;23(1):436. doi: 10.1186/s12916-025-04228-2.
2
Time Trends of Body Mass Index and its Impact on Glycemic Control Among Finnish Patients with Type 2 Diabetes.芬兰2型糖尿病患者体重指数的时间趋势及其对血糖控制的影响
Diabetes Ther. 2025 Jun 16. doi: 10.1007/s13300-025-01763-2.
3
Enhancing Therapy Adherence: Impact on Clinical Outcomes, Healthcare Costs, and Patient Quality of Life.

本文引用的文献

1
The role of depression and antidepressant treatment in antihypertensive medication adherence and persistence: Utilising electronic health record data.抑郁症及抗抑郁治疗在抗高血压药物依从性和持续性中的作用:利用电子健康记录数据
J Psychiatr Res. 2023 Dec;168:269-278. doi: 10.1016/j.jpsychires.2023.10.018. Epub 2023 Oct 27.
2
Nationwide health, socio-economic and genetic predictors of COVID-19 vaccination status in Finland.芬兰全国范围内的健康、社会经济和遗传因素对 COVID-19 疫苗接种状况的预测。
Nat Hum Behav. 2023 Jul;7(7):1069-1083. doi: 10.1038/s41562-023-01591-z. Epub 2023 Apr 20.
3
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
提高治疗依从性:对临床结局、医疗成本和患者生活质量的影响。
Medicina (Kaunas). 2025 Jan 17;61(1):153. doi: 10.3390/medicina61010153.
一个 12 基因药物遗传学检测面板以预防药物不良反应:一项开放标签、多中心、对照、集群随机交叉实施研究。
Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4.
4
Pharmacogenomics: current status and future perspectives.药物基因组学:现状与未来展望。
Nat Rev Genet. 2023 Jun;24(6):350-362. doi: 10.1038/s41576-022-00572-8. Epub 2023 Jan 27.
5
FinnGen provides genetic insights from a well-phenotyped isolated population.FinnGen 为一个表型良好的隔离人群提供了遗传学方面的见解。
Nature. 2023 Jan;613(7944):508-518. doi: 10.1038/s41586-022-05473-8. Epub 2023 Jan 18.
6
Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases.遗传预测因子与心血管代谢疾病终生药物使用模式。
Nat Med. 2023 Jan;29(1):209-218. doi: 10.1038/s41591-022-02122-5. Epub 2023 Jan 18.
7
Perception of risk of hypertension related complications and adherence to antihypertensive drugs: a primary healthcare based cross-sectional study.高血压相关并发症风险认知与降压药物依从性:一项基于初级医疗保健的横断面研究。
BMC Prim Care. 2022 Nov 29;23(1):303. doi: 10.1186/s12875-022-01918-1.
8
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.临床药物遗传学实施联盟指南:SLCO1B1、ABCG2 和 CYP2C9 基因型与他汀类药物相关的肌肉骨骼症状。
Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11.
9
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.临床药物遗传学实施联盟 CYP2C19 基因型和氯吡格雷治疗指南:2022 更新版。
Clin Pharmacol Ther. 2022 Nov;112(5):959-967. doi: 10.1002/cpt.2526. Epub 2022 Feb 8.
10
Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis.患有多种疾病的人群中药物不依从的流行率和预测因素:系统评价和荟萃分析。
BMJ Open. 2021 Sep 2;11(9):e044987. doi: 10.1136/bmjopen-2020-044987.